Analyzing Acutus Medical (NASDAQ:AFIB) & DexCom (NASDAQ:DXCM)

Acutus Medical (NASDAQ:AFIB) and DexCom (NASDAQ:DXCM) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations.

Valuation and Earnings

This table compares Acutus Medical and DexCom”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acutus Medical	$7.16 million	0.00	-$81.66 million	($0.11)	-0.00
DexCom	$4.66 billion	7.35	$836.30 million	$2.53	35.89

DexCom has higher revenue and earnings than Acutus Medical. Acutus Medical is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

56.9% of Acutus Medical shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 5.2% of Acutus Medical shares are held by insiders. Comparatively, 0.3% of DexCom shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations for Acutus Medical and DexCom, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acutus Medical	0	0	0	0	0.00
DexCom	1	3	21	2	2.89

DexCom has a consensus price target of $88.71, indicating a potential downside of 2.30%. Given DexCom’s stronger consensus rating and higher probable upside, analysts plainly believe DexCom is more favorable than Acutus Medical.

Risk and Volatility

Acutus Medical has a beta of 5.7, indicating that its share price is 470% more volatile than the S&P 500. Comparatively, DexCom has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.

Profitability

This table compares Acutus Medical and DexCom’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acutus Medical	-272.74%	-311.64%	-11.57%
DexCom	20.12%	35.94%	14.75%

Summary

DexCom beats Acutus Medical on 13 of the 15 factors compared between the two stocks.

About Acutus Medical

Acutus Medical, Inc. designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.

About DexCom

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.